KCAS expands ligand binding assay team

Proveen Dass joins the company as associate director

KCAS, a US bioanalytical laboratory specialising in research and analytical services for pharmaceutical, biotech, animal health and medical device companies, has expanded its large molecule analysis capabilities and in the process has hired Proveen Dass as associate director of its ligand binding assay (LBA) team.

Dass joins Masood Khan, senior director of immunoanalytical science and technology at the Shawnee, Kansas-based firm. He will assist with the development of GLP-compliant and non-GLP assays for the conduct of large molecule bioanalytical studies, including PK/TK analysis, immunogenicity evaluation and biomarker quantification.

KCAS uses state-of-the-art immunoanalytical technologies to support large molecule bioanalysis for preclinical and clinical studies (Phase I - IV), as well as rapid bioanalysis for biomarker screening pilot projects.

‘We are very fortunate to have both Dr Khan and Dr Dass at KCAS,’ said president and scientific director Dari Dadgar.

‘Their combined knowledge and skill in working with large molecules, specifically LBA services, has positively impacted our capabilities and we look forward to propelled growth and expansion in the future.’

KCAS has recently purchased Meso Scale Discovery’s Sector Imager 6000, an electrochemiluminescence (ECL) detection technology, which will enable the company to offer immunogenicity assays with better drug tolerance and multi-plex panels for biomarker assays.

You may also like

Research & Development

Amolyt receives FDA fast track designation for hypoparathyroidism drug

The therapeutic has been awarded the fast track designation owing to the Phase III Calypso trial, which showed promising efficacy and safety features
Manufacturing

The (r)evolution of biocatalysis in API synthesis

Explore Farmhispania Group’s enzyme toolbox to develop cost-effective, green-by-design synthetic routes for the cGMP production of your small-molecule NCEs
Manufacturing

PCI Pharma Services commences installation of sterile fill-finish and lyophilisation line

The Bedford, NH site will advance PCI's manufacturing capabilities with twin lyophilisers and a large-scale isolator filling line, making this the third sterile fill-finish facility built in the last three years
Manufacturing

From batch to continuous chemistry to continuous processing

The main challenge in many flow reactors lies in achieving a smooth and continuous flow within microchannels. Dec Group focuses on effectively transporting solid materials and engineering the flow to enhance chemical processes and increase their efficiency
Manufacturing

High speed, high shear mixers for the pharmaceutical industry

From laboratory scale mixers capable of handling as little as 1 mL to production-scale models, including hygienic and ultra-hygienic mixing equipment specifically designed for pharmaceutical applications, Silverson Machines has a vast product range
Manufacturing

Owen Mumford’s near-term and net-zero targets approved by the SBTi

The company's long and short-term initiatives include the reduction of scope 1, 2 and 3 emissions by 42% by 2030, as well as reaching net-zero in greenhouse gas emissions
Manufacturing

Adare expands global handling & packaging capabilities

The company will have enhanced compaction, milling, bin blending and tablet compression capabilities in Philadelphia, Ohio and Milan
Subscribe now